Pomalidomide API

Name	Pomalidomide
Chinese name	泊马度胺
Cas Number	19171-19-8
Source	India
Qualifications	USDMF/-/-/-/-

Pomalidomide is a third-generation Thalidomide analogue launched by Celgene. The drug was approved by the FDA in February 2013 and approved by the EMA in August 2013. It is by far the most active immunomodulatory drug. The drug can be used to effectively treat multiple myeloma (Multiple Myeloma, MM) at a very low dose, thereby reducing the risk of adverse events, including peripheral neuropathy and bone marrow suppression. (The dose of pomalidomide is 4 mg, while lenalidomide is 25mg, 800mg for thalidomide). Pomalidomide has a good response to MM that is ineffective in lenalidomide and thalidomide treatment, and it also shows a higher remission rate for MM patients refractory to other new drugs. Pomalidomide is the third immunomodulatory drug after lenalidomide and thalidomide. The approval of pomalidomide opens a new window for patients who have failed to treat other drugs. Pomalidomide will be the future One of the imitation hot spots of this indication in a few years.

Hot Tags: pomalidomide api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Perindopril Tert butylamine Salt API, Tippyridine Hydrochloride API, Tetrabenazine API, Valganciclovir Hydrochloride API, Edoxaban API, Pregabalin API

• Previous: Lenvatinib Mesylate API
• Next: Carfilzomib API